ArticleScientific reports2026
Biomolecular strategy for designing antibiotic-silver nanoparticles conjugate via nitrate reductase mediated β-lactamase inhibition with molecular docking insights.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Silver Nanoparticles in Donkey Semen Stored at 17°C: Effect on Sperm Parameters and Bacterial Growth.Reproduction in domestic animals = Zuchthygiene · 2026Article
- Biologically Mediated Nanoparticle Synthesis as a Potential Green Strategy: Principles, Methods, and Pharmaceutical Applications.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, mechanistic analysis using SDS-PAGE identified a 58 kDa protein as the biomolecule responsible for AgNPs biosynthesis and capping. Colorimetric microplate-based assay confirmed the protein as nitrate reductase, with structural preservation evidenced by a 29.68% activity increase (1.856 to 2.407 U/g) following AgNPs synthesis. Functionalization of AgNPs with ampicillin was indicated by SPR shift from 422.5 to 340.5 nm and disappearance of the FTIR band at 1736 cm⁻¹. Amp-AgNPs conjugate was stable (3 months), semi-spherical crystalline, polydisperse (PDI: 0.192), average diameter of 27.26 nm, zeta potential of - 24.9 mV, and showed broad pH (1-9) and thermal (5-55 °C) stability. Docking analysis revealed strong binding of ampicillin within the nitrate reductase catalytic pocket through hydrogen bonding, hydrophobic, and electrostatic interactions, confirming the conjugate stability. Amp-AgNPs (50 µg/mL) exhibited potent antibacterial activity against β-lactamase-producing bacteria with inhibition zones of 27.3 mm (Escherichia coli), 25.0 mm (Enterococcus faecalis), and 26.3 mm (Staphylococcus aureus), and MICs of 3.3, 4.7, and 4.3 µg/mL, respectively. SEM analysis revealed severe structural changes, indicating synergistic membrane disruption and antibiotic delivery. Amp-AgNPs potently inhibited β-lactamase in the iodometric assay, supporting their potential as alternative therapeutic agents. Future studies should focus on in vivo efficacy and expand this strategy to additional drug delivery applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.